Between the 25th and 29th of September, the PURPOSE 1 Clinical Operations Team, Irina Niculae, and Charlotte Young visited the three Uganda sites to meet Principle Investigators and get to know site staff in-person. PURPOSE 1 is currently being conducted at MU-JHU Mityana, AMBSO-Masaka, and Makerere-Kalangala sites with MU-JHU Care Ltd. as the national coordinating institution.
At the MU-JHU Mityana site, the two officials toured the MU-JHU Mityana Research Facility as well as the communities where study participants were recruited from – bars, health facilities and towns near the gold mine in Mubende.
‘’It was a pleasure hosting Irina and Charlotte at the three Uganda sites. We are glad the sponsor representatives were able to appreciate our site set up. This includes the level of commitment towards PURPOSE 1 by the different study teams, the set-up of the communities where our participants come from, the effort involved in not only recruiting but also retaining study participants, and the innovative ways devised to keep the young girls engaged with the study for the remaining years. Special thanks to Gilead Sciences Inc., the Study sponsor’’, Dr. Flavia Matovu Kiweewa, National Principal Investigator.
About PURPOSE 1
This study is funded by Gilead Sciences Inc. and is evaluating the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV—also known as pre-exposure prophylaxis (PrEP). It is being conducted in South Africa and Uganda.